Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial

• Published in: The European respiratory journal Vol. 63; no. 4; p. 2301768
• Main Authors: Murray, Rachael L, Alexandris, Panos, Baldwin, David, Brain, Kate, Britton, John, Crosbie, Philip A J, Gabe, Rhian, Lewis, Sarah, Parrott, Steve, Quaife, Samantha L, Tam, Hui Zhen, Wu, Qi, Beeken, Rebecca, Copeland, Harriet, Eckert, Claire, Hancock, Neil, Lindop, Jason, McCutchan, Grace, Marshall, Catriona, Neal, Richard D, Rogerson, Suzanne, Quinn Scoggins, Harriet D, Simmonds, Irene, Thorley, Rebecca, Callister, Matthew E
• Format: Journal Article
• Language: English
• Published: England European Respiratory Society 01.04.2024
• Subjects: Community Health Services; Humans; Lung; Male; Original s; Smoking Cessation - methods; Tobacco Use Disorder; Tomography
• ISSN: 0903-1936; 1399-3003
• DOI: 10.1183/13993003.01768-2023

Up to 50% of those attending for low-dose computed tomography screening for lung cancer continue to smoke and co-delivery of smoking cessation services alongside screening may maximise clinical benefit. Here we present data from an opt-out co-located smoking cessation service delivered alongside the Yorkshire Lung Screening Trial (YLST). Eligible YLST participants were offered an immediate consultation with a smoking cessation practitioner (SCP) at their screening visit with ongoing smoking cessation support over subsequent weeks. Of 2150 eligible participants, 1905 (89%) accepted the offer of an SCP consultation during their initial visit, with 1609 (75%) receiving ongoing smoking cessation support over subsequent weeks. Uptake of ongoing support was not associated with age, ethnicity, deprivation or educational level in multivariable analyses, although men were less likely to engage (adjusted OR (OR ) 0.71, 95% CI 0.56-0.89). Uptake was higher in those with higher nicotine dependency, motivation to stop smoking and self-efficacy for quitting. Overall, 323 participants self-reported quitting at 4 weeks (15.0% of the eligible population); 266 were validated by exhaled carbon monoxide (12.4%). Multivariable analyses of eligible smokers suggested 4-week quitting was more likely in men (OR 1.43, 95% CI 1.11-1.84), those with higher motivation to quit and previous quit attempts, while those with a stronger smoking habit in terms of cigarettes per day were less likely to quit. There was high uptake for co-located opt-out smoking cessation support across a wide range of participant demographics. Protected funding for integrated smoking cessation services should be considered to maximise programme equity and benefit.